187 related articles for article (PubMed ID: 33942633)
21. Diagnostic value of carcinoembryonic antigen and carcinoma antigen 19-9 for colorectal carcinoma.
Zhang SY; Lin M; Zhang HB
Int J Clin Exp Pathol; 2015; 8(8):9404-9. PubMed ID: 26464695
[TBL] [Abstract][Full Text] [Related]
22. Plasma TIMP-1 and CEA in detection of primary colorectal cancer: a prospective, population based study of 4509 high-risk individuals.
Nielsen HJ; Brünner N; Jorgensen LN; Olsen J; Rahr HB; Thygesen K; Hoyer U; Laurberg S; Stieber P; Blankenstein MA; Davis G; Dowell BL; Christensen IJ; ;
Scand J Gastroenterol; 2011 Jan; 46(1):60-9. PubMed ID: 20799911
[TBL] [Abstract][Full Text] [Related]
23. Plasma TIMP-1 and CEA as Markers for Detection of Primary Colorectal Cancer: A Prospective Validation Study Including Symptomatic and Non-symptomatic Individuals.
Christensen IJ; Brünner N; Dowell B; Davis G; Nielsen HJ; Newstead G; King D
Anticancer Res; 2015 Sep; 35(9):4935-41. PubMed ID: 26254391
[TBL] [Abstract][Full Text] [Related]
24. Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy.
Leelawat K; Sakchinabut S; Narong S; Wannaprasert J
BMC Gastroenterol; 2009 Apr; 9():30. PubMed ID: 19405942
[TBL] [Abstract][Full Text] [Related]
25. The diagnostic value of serum carcino-embryonic antigen, alpha fetoprotein and carbohydrate antigen 19-9 for colorectal cancer.
Wang YR; Yan JX; Wang LN
J Cancer Res Ther; 2014 Dec; 10 Suppl():307-9. PubMed ID: 25693941
[TBL] [Abstract][Full Text] [Related]
26. Matrix metalloproteinase-9,-3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: relationship to clinicopathological variables.
Işlekel H; Oktay G; Terzi C; Canda AE; Füzün M; Küpelioğlu A
Cell Biochem Funct; 2007; 25(4):433-41. PubMed ID: 16615041
[TBL] [Abstract][Full Text] [Related]
27. Clinical Value of Serum CEA, CA24-2 and CA19-9 in Patients with Colorectal Cancer.
Rao H; Wu H; Huang Q; Yu Z; Zhong Z
Clin Lab; 2021 Apr; 67(4):. PubMed ID: 33865243
[TBL] [Abstract][Full Text] [Related]
28. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
[TBL] [Abstract][Full Text] [Related]
29. Value of combined serum CEA, CA72-4, and CA19-9 marker detection in diagnosis of colorectal cancer.
Kildusiene I; Dulskas A; Smailyte G
Tech Coloproctol; 2024 Feb; 28(1):33. PubMed ID: 38358422
[TBL] [Abstract][Full Text] [Related]
30. Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) in preoperative serum as independent prognostic markers in patients with colorectal cancer.
Dragutinović VV; Radonjić NV; Petronijević ND; Tatić SB; Dimitrijević IB; Radovanović NS; Krivokapić ZV
Mol Cell Biochem; 2011 Sep; 355(1-2):173-8. PubMed ID: 21541674
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathologic and prognostic significance of matrix metalloproteinases in rectal cancer.
Schwandner O; Schlamp A; Broll R; Bruch HP
Int J Colorectal Dis; 2007 Feb; 22(2):127-36. PubMed ID: 16896992
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer.
Hilska M; Roberts PJ; Collan YU; Laine VJ; Kössi J; Hirsimäki P; Rahkonen O; Laato M
Int J Cancer; 2007 Aug; 121(4):714-23. PubMed ID: 17455256
[TBL] [Abstract][Full Text] [Related]
33. Matrix metalloproteinase 2 (MMP-2) and its tissue inhibitor 2 (TIMP-2) in pancreatic cancer (PC).
Łukaszewicz-Zając M; Gryko M; Pączek S; Szmitkowski M; Kędra B; Mroczko B
Oncotarget; 2019 Jan; 10(3):395-403. PubMed ID: 30719232
[TBL] [Abstract][Full Text] [Related]
34. Clinical relevance of MMP-9, MMP-2, TIMP-1 and TIMP-2 in colorectal cancer.
Morán A; Iniesta P; García-Aranda C; De Juan C; Díaz-López A; Sánchez-Pernaute A; Torres AJ; Díaz-Rubio E; Balibrea JL; Benito M
Oncol Rep; 2005 Jan; 13(1):115-20. PubMed ID: 15583811
[TBL] [Abstract][Full Text] [Related]
35. Preoperative serum carcinoembryonic antigen, carbohydrate antigen19-9 and carbohydrate antigen 125 as prognostic factors for recurrence-free survival in colorectal cancer.
Yang XQ; Chen C; Wang FB; Peng CW; Li Y
Asian Pac J Cancer Prev; 2011; 12(5):1251-6. PubMed ID: 21875276
[TBL] [Abstract][Full Text] [Related]
36. TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer.
Spindler KL; Christensen IJ; Nielsen HJ; Jakobsen A; Brünner N
Tumour Biol; 2015 Jun; 36(6):4301-8. PubMed ID: 25608838
[TBL] [Abstract][Full Text] [Related]
37. TIMP-2 inhibits metastasis and predicts prognosis of colorectal cancer via regulating MMP-9.
Wang W; Li D; Xiang L; Lv M; Tao L; Ni T; Deng J; Gu X; Masatara S; Liu Y; Zhou Y
Cell Adh Migr; 2019 Dec; 13(1):273-284. PubMed ID: 31293204
[TBL] [Abstract][Full Text] [Related]
38. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
39. TNM staging for GIT cancers is correlated with the level of MMPs and TGF-β1.
El-Ashmawy NE; Khedr NF; Mansour MG; Al-Ashmawy GM
Clin Exp Med; 2020 Nov; 20(4):545-555. PubMed ID: 32772210
[TBL] [Abstract][Full Text] [Related]
40. The prognostic role of tissue and serum MMP-1 and TIMP-1 expression in patients with non-small cell lung cancer.
An HJ; Lee YJ; Hong SA; Kim JO; Lee KY; Kim YK; Park JK; Kang JH
Pathol Res Pract; 2016 May; 212(5):357-64. PubMed ID: 26995105
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
